Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04626 (
erbB-2
)
5,251
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
MLN64
gene, which is localized in q12-q21 of the human chromosome 17, encodes a novel protein containing 2 distinct domains. At the N-terminal,
MLN64
exhibits a potential trans-membrane region, while at the C-terminal, it shares homology with the F26F4.4 protein of Coenorhabditis elegans and the steroidogenic acute regulatory (StAR) protein, a mitochondrial protein which is involved in steroid-hormone synthesis. By comparing the C-terminal part of these proteins, we defined a novel protein domain, which we termed SHD for "StAR Homology Domain". Of the 93 primary invasive breast carcinomas that were examined, 14 were found to over-express
MLN64
. These 14 tumors also expressed high c-
erbB-2
transcript levels, which were not detected in the
MLN64
-negative tumors.
MLN64
mRNA and protein were specifically detected in malignant cells of breast carcinomas.
MLN64
protein was localized within bundle-like structures distributed throughout the cell cytoplasm and condensed in a perinuclear patch, suggesting an association with a specific cell compartment. When the N-terminal part of
MLN64
was deleted,
MLN64
was uniformly distributed in the cell cytoplasm, indicating that N-terminal part is involved in the specific cytoplasmic localization of
MLN64
. The homology between the C-terminal part of
MLN64
and the functional StAR domain (SHD) suggests that
MLN64
and StAR, although distributed in different cellular compartments, may both play a role in steroidogenesis. In this case, the high levels of
MLN64
observed in some breast carcinomas could contribute to the progression of these tumors through increased intratumoral steroidogenesis.
...
PMID:MLN64 exhibits homology with the steroidogenic acute regulatory protein (STAR) and is over-expressed in human breast carcinomas. 913 40
MLN64
, is invariably coamplified and coexpressed with
erbB-2
in breast cancers. The human
MLN64
and ERBB2 genes are positioned at less than 50 kb from each other, on chromosome 17q12. To understand the molecular basis of
MLN64
overexpression in cancer, the genomic region containing the
MLN64
and ERBB2 genes was isolated and mapped. The two genes, DARPP32 and Telethonin, flanking
MLN64
respectively on its centromeric and telomeric sides, although coamplified, are not overexpressed in breast cancer cells, indicating that gene amplification is not sufficient to allow overexpression. The
MLN64
minimal promoter was isolated and found to be a housekeeping gene promoter containing four potential Sp1 binding elements. Using Sp1-deficient Drosophila SL2 cells,
MLN64
promoter activity was induced in a dose-dependent manner by exogenous Sp1 addition. Furthermore, mutation of each individual Sp1 element resulted in a significant decrease in reporter gene activity, indicating that all the Sp1 binding elements are functional and act together to promote gene expression. Since the ERBB2 promoter is also positively regulated by Sp1, this study indicates that
MLN64
and ERBB2 genes share common transcriptional controls together with a physical link on chromosome 17q. We speculate that, in addition to the oncogenic potential of
erbB-2
overexpression, the unbalanced action of
MLN64
contributes to the poor clinical outcome of breast tumors bearing this amplified region.
...
PMID:Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp/KLF transcription factors. 1280 84